• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pasithea Therapeutics Corp. - Common Stock (NQ:KTTA)

    0.8610 +0.0010 (+0.12%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Pasithea Therapeutics Corp. - Common Stock

    News headline image
    Kartoon Studios Mainframe Studios, Toon Media, and Premium IP Pipeline Drive 2026-2027 Outlook
    Via AB Newswire
    Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
    EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
    From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
    Via Business Wire
    Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
    Learn More about Pasithea Therapeutics by gaining access to the latest research report 
    Via TheNewswire.com
    News headline image
    Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
    From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
    Via Business Wire
    News headline image
    Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
    From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
    Via Business Wire
    Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
    Via Get News
    News headline image
    Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
    From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
    Via Business Wire
    Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
    Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
    Via FinancialNewsMedia
    News headline image
    Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
    From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
    Via Business Wire
    News headline image
    Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
    From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
    Via Business Wire
    Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
    Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
    Via FinancialNewsMedia
    News headline image
    Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
    From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.
    Via Business Wire
    News headline image
    Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
    From Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
    Via Business Wire
    PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
    Via Investor Brand Network
    Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
    Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... 
    Via FinancialNewsMedia
    Topics Economy
    Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
    Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
    Via FinancialNewsMedia
    Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
    Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
    Via FinancialNewsMedia
    Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
    Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
    Via FinancialNewsMedia
    Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
    Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market.... 
    Via FinancialNewsMedia
    Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
    Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
    Via FinancialNewsMedia
    Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
    Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
    Via FinancialNewsMedia
    Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
    Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the... 
    Via FinancialNewsMedia
    Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
    Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... 
    Via FinancialNewsMedia
    News headline image
    SmallCapsDaily: Pasithea Therapeutics Emerges as a Major Player in the Biotech Industry
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.